Yesterday, MELA Sciences announced that it has entered into a two-year agreement with Quintiles Commercial Germany GmbH. As per the agreement, Quintiles will provide customer service, sales, and management support to MELA Sciences to supplement the commercialization and launch of MelaFind in Germany.
“We are enthusiastic to be working with Quintiles as we execute our commercialization strategy in Germany,” said Dr. Joseph V. Gulfo, President and CEO of MELA Sciences. “Quintiles is a premier contract sales organization (CSO) with a 20-year history of providing commercialization support in Germany. They are providing us a tailored, economical and expandable solution that is ideally suited to our controlled and deliberate strategy.”
MELA Sciences is a medical device company that is currently working towards commercializing its flagship product, MelaFind®. MelaFind is a non-invasive tool that provides additional information to dermatologists during melanoma skin examinations. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin, providing additional objective information that may be used by dermatologists in the biopsy decision-making process. MelaFind has been approved by the FDA for use in the U.S.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
